Posted: November 21st, 2016
Idenix Pharmaceuticals Inc. v. Gilead Sciences Inc., Court of Appeal, London, UK, 8 November 2016, Case no. [2016] EWCA Civ 1089 The Court of Appeal has upheld Arnold J’s judgment on the Gilead v Idenix case, which concerned the validity of Idenix’s patent EP(UK)1 523 489 covering a family of nucleoside analogues for the treatment […]
READ MOREPosted: October 17th, 2016
Warner-Lambert Company LLC v (1) Generics (UK) Limited (trading as Mylan), (2) Actavis Group PTC EHF, (3) Actavis UK Limited and (4) Caduceus Pharma Limited, England and Wales Court of Appeal (Floyd, Pattern and Kitchin LJJ), London UK, 13 October 2016, Neutral Citation Number: [2016] EWCA Civ 1006 The Court of Appeal dismissed Warner-Lambert’s appeal […]
READ MOREPosted: July 21st, 2016
Idenix Pharmaceuticals, Inc. together with Centre National de la Recherche Scientifique, Università degli Studi di Cagliari and L’Université Montpellier II were the proprietors of Norwegian patent NO 330 755. The patent was directed to certain nucleoside analogues with anti-viral activity. Amongst the compounds covered by NO 330 755 was sofosbuvir which is the active ingredient […]
READ MOREPosted: May 20th, 2016
GlaxoSmithKline UK Limited v Wyeth Holdings LLC, High Court of Justice of England & Wales (Patents Court), London, UK, Carr J, 12 May 2016, Neutral Citation Number: [2016] EWHC 1045 (CH) Carr J has upheld the validity of Wyeth’s patent EP(UK) 2,343,308 relating to a combination product comprising a 2086 protein and a PorA protein […]
READ MOREPosted: May 3rd, 2016
Ajinomoto Co. Inc. and Ajinomoto Eurolysine A.S. v. Global Bio-Chem Technology Group Company Limited et al., Court of Appeal the Hague, the Netherlands, 26 April 2016, Case No. 200-161.842/01 Ajinomoto appealed the judgment in which the District Court (in the counterclaim) invalidated Ajinomoto’s patent EP 1664318 relating to the the production of L-lysine and in […]
READ MOREPosted: February 16th, 2016
Regeneron Pharmaceuticals Inc v Kymab Limited and Novo Nordisk A/S, High Court of England and Wales (Carr J), London, UK, 1 February 2016, Neutral Citation Number: [2016] EWHC 87 (Pat). On 3 February 2016 the Patents Court (Carr J) held that the disputed claims of two of Regeneron’s patents relating to transgenic mice used for […]
READ MOREPosted: December 7th, 2015
Actavis Group PTC EHF & Anor v Eli Lilly and Company, High Court of England and Wales (Carr J), London, UK, 16 November 2015, Neutral Citation Number: [2015] EWHC 3294 (Pat) This was an action by Actavis to “clear the way” in relation to atomoxetine, the first non-stimulant to be approved for the treatment of […]
READ MOREPosted: June 10th, 2015
Synthon v Teva, London, UK, 21 May 2015, [2015] EWCH 1395 (Pat) Birss J In his judgment of 21 May 2015, Birss J upheld the validity a number of claims of EP’528 and EP’924, both owned by Teva and relating to glatiramer acetate (“GA”). This was so notwithstanding that the Dutch designations of the same […]
READ MOREPosted: January 5th, 2015
Idenix Phamaceuticals, Inc v Gilead Sciences, Inc and Gilead Sciences Ltd and Centre National de la Recherche Scientifique and Universita Degli Studi de Cagliari and L’Universite Montpellier II, Patents Court, Neutral Citation Number: [2014] EWHC 3916 (Pat) The UK Patents Court has held, in a judgment handed down on 1 December 2014, that European Patent […]
READ MORE